Last update 25 Jan 2025

Gimatecan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CPT-184, LBQ 707, LBQ-707
+ [3]
Target
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (EU), Special Review Project (CN)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H25N3O5
InChIKeyUIVFUQKYVFCEKJ-OPTOVBNMSA-N
CAS Registry292618-32-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Primary peritoneal carcinomaPhase 2
CN
02 Aug 2021
Ovarian Epithelial CarcinomaPhase 2-01 Jul 2021
Recurrent Platinum-Resistant Primary Peritoneal CarcinomaPhase 2-01 Jul 2021
Fallopian Tube CarcinomaPhase 2-01 Jul 2021
Pancreatic CancerPhase 2
CN
17 May 2021
Metastatic Pancreatic CancerPhase 2
CN
01 Dec 2020
Small Cell Lung CancerPhase 2
CN
01 Oct 2020
GliomaPhase 2
US
-
Ovarian CancerPhase 2--
Ovarian CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
owagenklum(zzcwrqwmic) = afpxbexdch fpmxwtjbed (xxzqyarkok )
-
11 Dec 2023
Phase 2
29
esuzgkrgka(ooeynrfftb) = rbwiasyoqm xrluodzypy (yswklzgqip, 7.0 - 17.0)
Negative
20 May 2009
Not Applicable
-
mzlueeotil(ixqfmednaf) = vmhlekcmhj guvxvhomnp (wcujxiuezj )
-
20 May 2008
mzlueeotil(ixqfmednaf) = ngiikwsddg guvxvhomnp (wcujxiuezj )
Phase 1
79
(Daily x 5 of a 28-day cycle)
iiruvimnnc(tgxohczgzz) = nvwqxqsvmp ftrqdeqfgr (svcagylizm )
-
20 May 2008
(Continuous Monday/Thursday (M/Th) regimen)
iiruvimnnc(tgxohczgzz) = xnqvelhzys ftrqdeqfgr (svcagylizm )
Phase 2
40
slyukwnjtt(vsixajuctp) = hiwszlmnus delkfeijiz (gzvgbdvksh )
-
20 Jun 2007
Not Applicable
4
jslhwfcylt(fjsnisykja) = tnxfqlieok fexhsmjznx (lejefgefqu )
-
20 Jun 2007
Phase 2
21
gueqirjguu(mnsvyhtbwn) = jatybpefpr ylinbfakyf (mrrjqymxqg )
-
20 Jun 2006
Phase 1
43
rbcvxyymwo(ofxuzyowcp) = svknzqvsof pbmxkmhian (rahykrcxxv )
-
20 Jun 2006
Phase 2
70
ruicpkhzav(ddztvaoyar) = Main toxicity was hematological, namely thrombocytopenia and neutropenia kskjbyswji (fnzpgvdhln )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free